<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623606</url>
  </required_header>
  <id_info>
    <org_study_id>CMCB2B0X</org_study_id>
    <nct_id>NCT04623606</nct_id>
  </id_info>
  <brief_title>Boost to Brittle Bones - Stem Cell Transplantation for Treatment of Brittle Bones</brief_title>
  <acronym>BOOST2B</acronym>
  <official_title>Exploratory, Open Label, Multiple Dose, Phase I/II Trial Evaluating Safety, Efficacy of Intravenous and Intraosseous Infusion of Allogeneic Fetal Mesenchymal Stem In Treatment of Severe Osteogenesis Imperfecta Compared With Historical and Untreated Prospective Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Christian Medical College, Vellore, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, India</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vinnova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Christian Medical College, Vellore, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An exploratory, open label, multiple dose, phase I/II trial (n=15) evaluating safety and&#xD;
      efficacy of intravenous and intraosseous infusion of allogeneic expanded fetal mesenchymal&#xD;
      stem cells (MSC) for the treatment of severe Osteogenesis Imperfecta (OI) compared with&#xD;
      historical and untreated prospective controls.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Historical and Untreated prospective control and Treatment group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>The primary endpoint is safety and tolerability measured as seriousness, severity and frequency of treatment related adverse events (AEs)/Serious AE (SAE)/Suspected Unexpected Serious Adverse Reaction (SUSAR)with specific focus on the following:&#xD;
Vital signs in conjunction with the MSC infusion&#xD;
Transfusion reactions (infusion toxicity, embolism, allergy, infections)&#xD;
Immune reaction towards the cells, donor-specific antibodies, graft rejection, Graft versus Host Disease, autoimmunity)&#xD;
Tumourigenicity&#xD;
Mortality/morbidity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of fractures [ Time Frame: From baseline to 16 months follow-up ]</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Number of fractures.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (days) to first fracture after each stem cell administration. [ Time Frame: From each dose of stem cells to the time point of the first fracture.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Time (days) to first fracture after each stem cell administration. Number of fractures</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bone-marrow density (g/cm2). [ Time Frame: From baseline to the primary follow-up (From baseline to 16 months follow up)</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Change in bone-marrow density (g/cm2).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Growth (cm). [ Time Frame: From baseline to16 months follow up]</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Growth (cm) as assessed by clinician</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight (kg). [ Time Frame: From baseline to 16 months follow up]</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Growth (kg) as assessed by clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in clinical status of OI. [ Time Frame: From baseline to 16 months follow up]</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Change in clinical status of OI based on parameters defined under efficacy assessments described in protocol, as assessed by OI clinician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers P-Calcium (mg %) in blood samples.</measure>
    <time_frame>From at baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker P-Calcium (mg %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers P-Phosphate (mg %) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker P-Phosphate (mg %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers P-Albumin (g/dL)</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker P-Albumin (g/dL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers S-ALP (IU/L) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker S-ALP (IU/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers S-CTx (mg %) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker S-CTx (mg %)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers fP-PTH (pg/mL)in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker fP-PTH (pg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers Vitamin D (nmol/L) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker Vitamin D (nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers Bone specific S-ALP (μg/L) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker Bone specific S-ALP (μg/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers S-Osteocalcin (ng/mL) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker S-Osteocalcin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of biochemical bone turnover by analysis of the markers U-DPD/Krea and U-NTx/Krea (mg %) in blood samples.</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Assessment of biochemical bone turnover marker U-DPD/Krea and U-NTx/Krea (mg %)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Impact on the subjects Quality of Life: Pediatric Quality of Life Questionnaire™ (PedsQOL) [ Time Frame: From baseline to the 16 month follow-up</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Quality of life assessed using the Infant Pediatric Quality of Life Questionnaire™ (PedsQOL).</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of donor cells engrafted into patient tissue samples assessed by histology. [ Time Frame: From baseline to the 16 month follow up</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Donor cell engraftment.</description>
  </other_outcome>
  <other_outcome>
    <measure>Analysis of an array of cytokines and micro vesicles to evaluate paracrine effects. [ Time Frame: From baseline to the 16 month follow up</measure>
    <time_frame>From baseline to 16 months follow up</time_frame>
    <description>Paracrine effects will be analysed from plasma isolated from peripheral blood.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Osteogenesis Imperfecta</condition>
  <arm_group>
    <arm_group_label>Prospective Control (Untreated) and historical controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects eligible for the trial but not willing/able to participate in any of the experimental arms Matched historical controls. Subjects will be identified in historical registries and data will be retrieved from OI database</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of four doses of BOOST cells with the first dose between 1-4 years of age and the three additional doses at +4, +8 and +12 months after the first dose. Each dose is 3x10^6 MSC/kg body weight.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BOOST cells</intervention_name>
    <description>Four doses of expanded human 1st trimester fetal liver-derived mesenchymal stem cells.</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        (i)Inclusion Criteria Treatment group&#xD;
&#xD;
          1. Parent's/legal guardian's signed informed-consent form&#xD;
&#xD;
          2. Clinical diagnosis of OI type III or IV AND&#xD;
&#xD;
          3. Molecular diagnosis of OI (Glycine substitution in the collagen triple-helix encoding&#xD;
             region of either the COL1A1 or COL1A2 gene)&#xD;
&#xD;
          4. Age between 1 to 4 years&#xD;
&#xD;
          5. BP treatment initiated before inclusion&#xD;
&#xD;
          6. Parent/legal guardian over 18 years of age&#xD;
&#xD;
        (ii)Inclusion Criteria Prospective Untreated Control Group and Historical Control Group:&#xD;
&#xD;
          1. Parent's/legal guardian's signed informed-consent form&#xD;
&#xD;
          2. Clinical and molecular diagnosis of OI (Glycine substitution in the collagen&#xD;
             triple-helix encoding region of either the COL1A1 or COL1A2 gene)&#xD;
&#xD;
          3. Age between 4 to 8 years&#xD;
&#xD;
          4. Parent/legal guardian over 18 years of age&#xD;
&#xD;
        (iii)Exclusion Criteria Treatment group Prospective and historical control group:&#xD;
&#xD;
          1. Existence of other known disorder that might interfere with the treatment (such as&#xD;
             severe malformations, congenital heart defect, hypoxic encephalopathy (l-lll),&#xD;
             neurological problems, immune deficiencies, muscle diseases, syndromes) diagnosed by&#xD;
             clinical examination&#xD;
&#xD;
          2. Any contraindication for invasive procedures such as a moderate/severe bleeding&#xD;
             tendency or contagious infections&#xD;
&#xD;
          3. Abnormal karyotype or other confirmed genetic syndromes&#xD;
&#xD;
          4. Oncologic disease&#xD;
&#xD;
          5. Inability to comply with the trial protocol and evaluation and follow-up schedule&#xD;
&#xD;
          6. Inability to understand the information and to provide informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>8 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vrisha Madhuri, MS Orth</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian Medical College, Vellore, India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vrisha Madhuri, MS Orth</last_name>
    <phone>91-416-2282172</phone>
    <email>madhuriwalter@cmcvellore.ac.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Suhasini Ganesh, M.Pharm</last_name>
    <phone>91-416-2285117</phone>
    <email>brittlebonekids@cmcvellore.ac.in</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Christian Medical College</name>
      <address>
        <city>Vellore</city>
        <state>Tamil Nadu</state>
        <zip>632004</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suhasini Ganesh, M.Pharm</last_name>
      <phone>91-416-2285117</phone>
      <email>brittlebonekids@cmcvellore.ac.in</email>
    </contact>
    <contact_backup>
      <last_name>Suhasini Ganesh, M Pharm</last_name>
      <phone>91-416-2285117</phone>
      <email>brittlebonekids@cmcvellore.ac.in</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://boost2b.in/</url>
    <description>Boost to Brittle Bones</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>September 18, 2020</study_first_submitted>
  <study_first_submitted_qc>November 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Christian Medical College, Vellore, India</investigator_affiliation>
    <investigator_full_name>Vrisha Madhuri</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>OI, Brittle bone disease</keyword>
  <keyword>Hereditary bone fragility</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteogenesis Imperfecta</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

